Services & Model Systems

General Services

  1. Instrumentation and expertise for molecular and anatomic imaging
  2. Full range of services for preclinical testing in animals including
    • Model availability and development
    • Animal care and handling
    • Surgical procedures on small animals
    • Administration of therapeutics
    • Analysis of therapeutic safety and efficacy
    • Pharmacokinetic and pharmacodynamic analyses

Cancer-Related Services

  1. Model development specializing in imagable syngeneic tumor models administered orthotopically
  2. Availability of well characterized GEM, xenograft and syngeneic models for a wide range of cancers
  3. Drug target screening and validation
  4. Quantitative analysis of primary tumor growth and metastasis
  5. Full range of preclinical testing services for analysis of anti-cancer drugs and therapeutic regimens
    • Analysis of therapeutic safety, efficacy
    • Pharmacokinetics and pharmacodynamics
  6. Wide range of administration methods for tumors cells and therapeutics
  7. Immune and stromal cell profiling
  8. mage-guided injection and biopsy

Cancer Model Availability

Currently Available Luciferase-expressing Xenograft Models

  • MDA-MB-231 (breast, ER-) pdf
  • MCF-7 (breast, ER+) pdf
  • BT-474 (breast, ER+, HER2+)
  • PC-3M (prostate)
  • A549 (lung)
  • HT-29 (colon)
  • SKOV3 (ovarian)
  • HeLa (cervical)

Currently Available Luciferase-expressing Syngeneic Models

Patient-derived Xenograft (PDX) Models

The Facility is currently developing and banking patient-derived xenograft (PDX) models for breast and other cancers. These models, which are derived from well characterized patient tumors, involve expansion of tumor tissue in NOD/SCID/gamma (NSG) immunocompromised mice and subsequent implantation of tumor fragments in NSG mice for testing new drugs and therapeutic regimens. While PDX models, like other xenograft models, require the use of immunocompromised animals, they retain many of the characteristics of the tumors from which they were derived and provide a means of assessing the effects of therapeutics on specific cancer subtypes in a more physiological setting than can be achieved with conventional xenograft models.